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Introduction: this prospective study defines the immune response to fresh arterial homograft replacement for graft
infection.
Materials and methods: ten patients who underwent ABO-compatible homograft transplantation were studied for anti-
HLA antibody production, and CD3–CD4–CD8-positive lymphocytes subset. Immunological studies were performed
preoperatively, and at early (1, 3, 7 days) and late (1, 3, 6, 12, 18, 24 months) follow-up. All patients received
immunosuppressive treatment with cyclosporine (1–3 mg/kg/day). Abdominal CT scans were performed postoperatively
at the 1, 6, 12, 18, 24 months follow-up.
Results: preoperatively, antibodies could not be detected. Postoperatively, as from 1st month post-transplant, a progressive
increase in % PRA was observed in all patients, up to the 12th month of follow-up. Subsequently, at 18 and 36 months,
a progressive decrease in % PRA was detected. Data showed that the recipient antibodies were directed against donor-
specific antigens. During the immediate postoperative period (1, 3, 7 days) CD3- and CD4-positive T lymphocytes slightly
increased, whereas CD8 simultaneously decreased. Later, CD3 and CD4 progressively decreased and CD8 increased.
Clinically, all patients were cured of infection at late follow-up. CT scans showed thickening of the aortic wall (range:
2.5–4.5 mm), with no signs of aneurysmal degeneration.
Conclusions: fresh arterial homografts are immunogenic. Implanted homografts induce a strong anti-HLA antibody
response, similar to chronic rejection, in spite of immunosuppressive treatment.
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Introduction triggering an immune response similar to the rejection
process which develops in solid organ transplant re-
Aortoiliac graft infection has been successfully treated cipients.9–11
In a preliminary study we showed that human freshwith fresh or cryopreserved arterial homografts with
excellent short- and long-term results.1–4 However, few arterial homografts are immunogenic and trigger a
strong donor-specific anti-HLA antibody response.12clinical reports have investigated the immune response
in these patients either because arterial homografts are Evidence of a donor-specific antibody response has
also been found after implantation of homograft car-deemed to have a low antigenicity, or because graft
rejection is not thought to play a major role in clinical diac valves.13–18 This prospective study investigated
the late immune response to fresh arterial homograftoutcome. Therefore, arterial homografts are usually
transplanted without matching donor and recipient replacement for graft infection in a larger cohort of
arterial homograft recipients with a longer follow-up.for blood group (ABO) or human leukocyte antigens
(HLA). In addition, immunosuppressive therapy has We focused on when the immune response is initiated,
the antibody specificity, class and determinants, andbeen considered unsafe for use in patients with in-
fection. Some clinical studies have reported late com- the clinical outcome of the immune reaction.
plications due to graft rejection,5–8 which have been
confirmed in experimental models. Many animal stud-
ies have demonstrated strong homograft antigenicity
Materials and Methods
Ten men aged between 56 and 74 years (mean 65.3)* Please address all correspondence to: M. Mirelli, Servizio di Chi-
rurgia Vascolare, Via Massarenti 9, 40138 Bologna, Italy. who received fresh arterial homografts for aortoiliac
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(five patients) or aortobifemoral (five patients) pros- pendent Cytotoxicity (CDC) Test reveals cytotoxic anti-
thetic infections were enrolled in the study. Graft bodies in the recipient’s serum. Serum is fixed against
infection occurred early (within 4 months after sur- a panel of lymphocytes from 40 blood donors with
gery) in three cases and late in seven. The primary different HLA types. When the complement is added,
vascular operations were for abdominal aortic an- the presence of antibodies results in lymphocyte death.
eurysms (five) and aortoiliac occlusive diseases (five). The standard complement-dependent cytotoxicity
There were eight isolated primary prosthetic infections assay was performed in Terasaki microwell plates by
and two aortoenteric fistulas. Factors predisposing incubating 1 ll of mononuclear cells (3·106 cells/ml)
graft infections were: multiple vascular operations in with 1 ll of patient’s serum for 30 minutes at 22 °C.
four patients, rupture of aortic aneurysms in two cases After the addition of 5 ll of rabbit complement, plates
and surgical exposure of the groin in five patients. were again incubated for 60 minutes at 22 °C. Finally,
The clinical findings at time of graft infection included the cells were stained with 5 ll of acridine orange/
fever and/or leukocytosis (10 patients), false inguinal ethidium bromide solution: ethidium bromide stains
aneurysms (two patients), groin abscess (three dead cells whereas acridine orange stains live cells.
patients). Normal serum samples used as negative controls were
Surgical treatment included total removal of the placed among patient serum samples at a ratio of 1:
graft and its replacement in situ with fresh arterial 5. At light microscopy, the same experienced staff
allografts from cadaver donors with an identical ABO performed test evaluation. Panel reactive antibodies
blood group. The arteries had been removed during (PRA) were expressed as the percentage of lymphocyte
multiorgan explantation and stored at 4 °C in a modi- panel members against which the patient’s serum re-
fied RPMI solution and antibiotics1 for periods ranging acted and thus against which the patient has anti-
from 24 h to 7 days (mean: 72 h). The aortoenteric bodies. Samples showing more than 5% dead cells
fistulas were treated with intestinal resection and sub- above the background of negative controls were con-
sequent end-to-end anastomosis. Immunosuppressive sidered positive.19
treatment with cyclosporin was administered through- PRA-STAT-ELISA is an enzyme-linked immuno-
out the postoperative period (1–3 mg/kg/day i.v.). absorbent technique that simultaneously detects and
After discharge, oral cyclosporin was prescribed to identifies serum IgG directed against both HLA class
maintain blood levels between 100 and 200 lg/ml. All I and II antigens.24–27 Anti-HLA antibodies present in
patients received targeted or broad-spectrum antibiotic serum can be detected using soluble HLA (sHLA)
treatment for three months after surgery. Follow-up antigen-coated ELISA plates and enzyme-im-
was performed at 1, 3 and 6 months after surgery and munoassay techniques.24–27 Briefly, Elisa microplateevery 6 months thereafter, by clinical examination,
wells are coated with 44 different antigen preparations.colour Doppler ultrasound and CT scan to evaluate
Soluble HLA (sHLA) antigens are derived from dif-graft patency and any changes in thickness and dia-
ferent phenotyped cells representing 79 different HLAmeter of the arterial wall.
alleles. Each diluted serum specimen was added to
the 44 antigen-coated wells. During incubation, anti-
HLA antibodies present in serum bind to sHLA-an-Immunologic studies
tigen-coated wells. After incubation, wells were emp-
tied and washed to eliminate unbound material.Preoperatively, recipient and donor were typed for
Peroxidase-conjugated goat antihuman IgG antibodyABO blood group and HLA antigens. Serological19 and
was then added to microplate wells and reacted withgenomic20,21 techniques were utilised to identify class
bound anti-HLA IgG antibodies. Following washing toI (HLA-A, -B, -C) and II (HLA-DQ, -DR) HLA antigens
eliminate unbound conjugate, a chromogenic substraterespectively. The positive T-lymphocyte sub-
(o-phenylediamine solution: OPD) was added. In-population: CD3 (total T lymphocytes), CD4 (helper
tensity of colour development is proportional to theT lymphocytes), CD8 (cytotoxic/suppressor T lympho-
amount of conjugate bound to the well. Followingcytes) was determined in recipients by standard flow
addition of an acidic solution to stop colour de-cytometric techniques22,23 The recipient anti-HLA anti-
velopment, the adsorbance was measured on a mi-body production and antibody specificity was per-
croplate reader at a wavelength between 490–500 nmformed by standard National Institutes of Health
using a reference wavelength of 600–650 nm. In con-microlymphocytotoxicity technique (Complement-De-
trast to the lymphocytotoxicity (CDC) test, no cellpendent Cytotoxicity: CDC test)19 and enzyme-linked
preparation is necessary, and the composition of theimmunoabsorbent assay (PRA-STAT ELISA SangStat,
Nantes, France) respectively.24–27 The Complement-De- cell panel used to produce sHLA antigens will not
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Fig. 1. Postoperative (1 month) CT scan: the homograft shows an Fig. 2. Mean (–s.d.) percentage of pre- and postoperative Tarterial wall thickening (45 mm). lymphocytes subpopulation, with respect to total lymphocytes,
determined by flow-cytometry. (CD3: total T lymphocytes; CD4:
helper T lymphocytes; CD8: cytotoxic/suppressor T lymphocytes.vary from lot to lot. In addition, ELISA provides
Pre: preoperative; d: days; m: months)objective reading of results, using a microplate reader.
* p<0.05 vs. preoperative evaluation (Wilcoxon matched-pairs test).
Finally, donor lymphocytes were tested against re-
cipient’s serum (light microscopy and flow cytometric
cross-match): if pre-existing cytotoxic antibodies are
present (presensitisation), all lymphocytes or many of
them are severely damaged; when such conditions
occur, the test is considered positive.28–31 ABO com-
patibility and absence of preformed antibodies (Neg-
ative cross-match) were indispensable conditions for
homograft transplant. Postoperatively, early (at 1, 3, 7
days) and late (at 1, 3, 6, 12, 18, 24 months) testing
was performed, including CD3-, CD4-, CD8-positive
T lymphocytes assay, and serological search for anti-
HLA antibodies.
Statistical analysis Fig. 3. Mean (–s.d.) values of pre- and postoperative anti-HLA
antibodies production. Panel-reactive antibody in percentage
against a panel of lymphocytes (complement- dependent cytotoxicPercentages of positive T lymphocyte subpopulation test: CDC) and against a panel of different antigen preparations
and panel-reactive anti-HLA antibodies are reported (enzyme-immunoassay technique: PRASTAT). (Pre: preoperative;
m: months)as mean values–standard deviations (s.d.). The Wil-
* p<0.05 vs. preoperative evaluation (Wilcoxon matched-pairs test).coxon matched-pairs test was applied to compare data
evaluated after homografting vs. preoperative values.32
Early postoperative immunological studies of TStatistical analysis was performed by running the
lymphocytes subpopulations (Fig. 2), showed a sig-SPSS/PC+ statistical package on a personal com-
nificant increase in total T lymphocytes (CD3: after 3puter.33 A two-tailed p level equal to 0.05 was chosen
days and 7 days) and helper T lymphocytes (CD4:to assign the statistical significance.
after 3 days, 7 days and 1 month). The concomitant
decrease in cytotoxic/suppressor T lymphocytes (CD8)Results
did not reach significance. Later there was a gradual
reduction in CD3- and CD4-positive lymphocytes, ac-At late follow-up no patient showed evidence of re-
current infection. No complications related to immuno- companied by an increase in CD8 T lymphocytes.
No significant difference vs. preoperative values wassuppressive therapy were reported. Early and late CT
and ultrasonography scans were negative for ob- observed in the time period from 3 to 24 months after
surgery.structive or aneurysmal lesions of the homografts. On
the contrary, early CT scans revealed irregular arterial- Preoperatively, antibodies had not been detected by
either complement-dependent cytotoxicity test (CDC)wall thickening ranging from 2.5 to 4.5 mm in all but
one patient (Fig. 1), but this had subsided by late or enzyme immunoassay (PRA-STAT). As early as 1
month and as early as 3 months after transplantation,follow-up in all cases.
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Table 1. Specificity of human leukocytes antigens (HLA) antibody production. In bold
characters are visualised the recipient antibody specificities against HLA-non-compatible
donor’s antigens.
Patient No. Antibody Specificity Donor HLA type
1 B5, DQ1 A29-30; B5-18; DR6; DQ1; DQ3
2 A10; B15; B22; DR1; DR2; DQ1 A3-A10; B5-35; DR6; DQ1
3 A1; A9; A11; B8; DR3; DR7; DQ2 A1-A2; B7-B8; DR2-DR3; DQ1-DQ2
4 A2; A32; A33; B5; DR2; DR4; DQ1; A1-A30; B14-B35; DR2-DR4; DQ1-
DQ3 DQ3
5 A2; B5(w4); DQ3; DQ3(7) A1-A2; B5(w4); DR2-DR6, DQ1
6 B12; DR52 A3-A29; B12; DR6-DR7; DR52-
DR53; DQ1-DQ2
7 B5; DR5; DQ3 A3; B22-B35; DR5; DQ3
8 B13 A3; A10; B8-B13; DR4-DR7; DQ2-
DQ3
9 B8; B14; B16; B18; DR3; DR5; DQ2 A1-A3; B8-B35; DR3-DR5; DQ2-
DQ3
10 A9 A2-A9; B15-B35; DR6; DQ1
a significant increase in panel-reactive antibodies was follow-up are unknown, but the alloreactivity may
contribute to morphologic and functional changes indetected by CDC and PRA-STAT screening methods,
valve deterioration.13,17respectively (Fig. 3). PRA-STAT data showed that all
In addition to valve allografts, arterial and venoussera tested contained complex mixtures of anti-HLA
homografts are immunogenic because they expressclass I and class II antibodies. Most interestingly, the
both I and II class HLA antigens.10,11,38,39 In humans,recipient antibodies were specifically directed against
humoral (antibody) and cellular responses have beenthe antigens of the donor graft (Table 1).
described after saphenous-vein allograft bypass: the
formation of anti-HLA antibodies predicted graft fail-
ure in 90% of patients.40 After arterial homografting
Discussion in humans, few studies have investigated the humoral
immune response, even though histologic features
Arterial homografts have been advocated to treat are described as the immunological consequences of
aortoiliac graft infection, but the recipient’s immune arterial transplants.7,8 In arterial homograft re-
response has been poorly investigated, since arterial- placement for prosthetic infections, Ruotolo reported
wall antigenicity is not thought to play a major role typical signs of chronic rejection, i.e. intimal pro-
in homograft failures. Few data are available on the liferation of myofibroblastic cells, medial smooth-
immunogenicity of human arterial homografts, but muscle necrosis and adventitial inflammatory cell in-
our studies show that all recipients are likely to de- filtration, in 25% of external and femoral arterial al-
velop IgG reactions to donor HLA antigens. This lografts.8 In a sequential, experimental study of the
donor-specific response is similar to chronic rejection, cellular targets and immunological effectors of chronic
which occurs in the recipients of vascularised solid- arterial allograft rejection, Plissonier et al. described an
organ allografts.34–36 After heart transplantation, sera early adventitial inflammatory cell infiltration mainly
containing anti-HLA antibodies were significantly represented by macrophages and cytotoxic T lympho-
more common in patients who rejected, compared cytes (CD8).11 Inflammation persisted as long as
with successful heart allografts; the actuarial survival smooth-muscle cells survived, suggesting a possible
was 90% in patients not producing anti-HLA anti- chronic allo-antigenicity of medial smooth-muscle cell
bodies and 38% in antibody producers.37 Donor-spe- in arterial graft rejection. Smooth-muscle cells dis-
cific anti-HLA antibody production has been proved appear later, due to both humoral and cellular injury,
in patients submitted to fresh or cryopreserved valve as shown by IgG deposition surrounding smooth-
homograft, especially in the paediatric heart surgery muscle cells. Delayed intimal proliferation derives
cohort.13,15–18 Hogan et al. detected IgG antibodies to from the recipient’s response.11 Therefore, the initial
class I and II HLA in the serum of all aortic valve immune response seems to be cellular (lympho-
allograft recipients at 30 days after implantation, and cytotoxic) and the late reaction humoral (antibody),
antibodies persisted in all but one of the recipients at even if they are strictly correlated.
day 365.17 In valve homografts, the haemodynamic Our patients also experienced an early cellular im-
mune response after surgery consisting of an increaseconsequences of this antibody response on long-term
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in peripheral T lymphocytes (CD3) and the helper prospective cross-matching, immunosuppressive ther-
apy and preoperative manipulation of homografts tolymphocytes (CD4)-positive subpopulation together
reduce their antigenicity.with a concomitant reduction in cytotoxic/suppressor
lymphocytes (CD8), possibly because these cells are
mostly confined to the walls of the homograft. Instead,
their humoral (antibody) response appeared later, a
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